AGM Notice of Meeting – Telix Pharmaceuticals Limited
Telix Pharmaceuticals provides notice of The Annual General Meeting of the Shareholders on Tuesday 12 May 2020
Telix Pharmaceuticals Enters Commercial Distribution Agreement for Prostate Cancer Diagnostic
Telix Pharmaceuticals (U.S.) Inc. is pleased to announce it has entered into a commercial agreement with Cardinal Health
Telix Completes Acquisition of European Radiopharmaceutical Production Facility
Telix is pleased to announce it has now completed the acquisition of a licensed radiopharmaceutical production facility in Seneffe, Belgium
Telix Pharmaceuticals and partners receive $500K research grant from Government funded Innovative Manufacturing CRC
Telix and partners receive $500K research grant from Government-funded Innovative Manufacturing CRC to advance manufacturing of novel cancer drugs
Business Update : COVID-19
Telix provides an update on the Company’s risk management assessment of the novel coronavirus (COVID-19) pandemic.
Leader in Prostate Cancer Imaging Prof. Frederik L. Giesel Joins Scientific Advisory Board
Telix Pharmaceuticals Limited is pleased to announce that Professor Dr. Frederik L. Giesel, MD, MBA has joined Telix’s Scientific Advisory Board (SAB).
Positive FDA Feedback on NDA Submission Process for TLX591-CDx (kit for the preparation of 68Ga-PSMA-11)
Telix Pharmaceuticals announces that it has received positive feedback from the FDA regarding its submission of an NDA for TLX591-CDx
Telix Pharmaceuticals Releases Annual Report Year Ending 2019
Telix Pharmaceuticals Limited Releases Annual Report Year Ending 2019.
European Leadership Changes and Appointment of VP Sales and Marketing, EMEA
Telix Pharmaceuticals Limited announces that Ms Odile Jaume will be stepping down from her position of Telix EU President.
Telix Supports Molecular Imaging Summer Program at MSKCC
Telix Pharmaceuticals Ltd is pleased to announce our support of the Molecular Imaging Summer Program at MSKCC